Cargando…

Molecular docking analysis of lupeol with different cancer targets

Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunasekaran, Mahalakshmi, Ravi, Ravali, Subramanian, Kavimani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722432/
https://www.ncbi.nlm.nih.gov/pubmed/36518133
http://dx.doi.org/10.6026/97320630018134
_version_ 1784843973658935296
author Gunasekaran, Mahalakshmi
Ravi, Ravali
Subramanian, Kavimani
author_facet Gunasekaran, Mahalakshmi
Ravi, Ravali
Subramanian, Kavimani
author_sort Gunasekaran, Mahalakshmi
collection PubMed
description Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer cells. In recent drug designing, molecular study of analysis is usually used for understanding the target and the ligand interaction. Therefore, it is of interest to document the molecular docking analysis data of lupeol with different cancer targets such as Caspase- 3, BCL-2, Topoisomerase, PTK, mTOR, H-Ras, PI3K, and AKT. These molecular docking studies were carried out by using AutoDock tools 4.2 version software. Molecular docking analyses of lupeol with target protein were found to have good dock score and minimum inhibition constant. BCL-2, Topoisomerase, PTK, mTOR and PI3Kdocking studies showed the best binding energy inhibition constant and ligand efficiency. The in-silico molecular docking analysis showed that the lupeol having relatively good docking energy, affinity and efficiency towards the active macromolecule, thus it may be considered as good inhibitor of proliferating cancer cells. By this knowledge of docking results, the lupeol can be used as promising drug for anticancer activity.
format Online
Article
Text
id pubmed-9722432
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Biomedical Informatics
record_format MEDLINE/PubMed
spelling pubmed-97224322022-12-13 Molecular docking analysis of lupeol with different cancer targets Gunasekaran, Mahalakshmi Ravi, Ravali Subramanian, Kavimani Bioinformation Research Article Lupeol is one of the secondary metabolite (triterpenoid) present in many medicinally effective plants. It has numerous biological and pharmacological actions. Lupeol is found to have effective herbs and has immense biological activity against several diseases including its cytotoxic effect on cancer cells. In recent drug designing, molecular study of analysis is usually used for understanding the target and the ligand interaction. Therefore, it is of interest to document the molecular docking analysis data of lupeol with different cancer targets such as Caspase- 3, BCL-2, Topoisomerase, PTK, mTOR, H-Ras, PI3K, and AKT. These molecular docking studies were carried out by using AutoDock tools 4.2 version software. Molecular docking analyses of lupeol with target protein were found to have good dock score and minimum inhibition constant. BCL-2, Topoisomerase, PTK, mTOR and PI3Kdocking studies showed the best binding energy inhibition constant and ligand efficiency. The in-silico molecular docking analysis showed that the lupeol having relatively good docking energy, affinity and efficiency towards the active macromolecule, thus it may be considered as good inhibitor of proliferating cancer cells. By this knowledge of docking results, the lupeol can be used as promising drug for anticancer activity. Biomedical Informatics 2022-03-31 /pmc/articles/PMC9722432/ /pubmed/36518133 http://dx.doi.org/10.6026/97320630018134 Text en © 2022 Biomedical Informatics https://creativecommons.org/licenses/by/3.0/This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
spellingShingle Research Article
Gunasekaran, Mahalakshmi
Ravi, Ravali
Subramanian, Kavimani
Molecular docking analysis of lupeol with different cancer targets
title Molecular docking analysis of lupeol with different cancer targets
title_full Molecular docking analysis of lupeol with different cancer targets
title_fullStr Molecular docking analysis of lupeol with different cancer targets
title_full_unstemmed Molecular docking analysis of lupeol with different cancer targets
title_short Molecular docking analysis of lupeol with different cancer targets
title_sort molecular docking analysis of lupeol with different cancer targets
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722432/
https://www.ncbi.nlm.nih.gov/pubmed/36518133
http://dx.doi.org/10.6026/97320630018134
work_keys_str_mv AT gunasekaranmahalakshmi moleculardockinganalysisoflupeolwithdifferentcancertargets
AT raviravali moleculardockinganalysisoflupeolwithdifferentcancertargets
AT subramaniankavimani moleculardockinganalysisoflupeolwithdifferentcancertargets